ASH 2022 | Ongoing trials investigating the efficacy of pirtobrutinib in CLL

Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines ongoing investigations on pirtobrutinib, a non-covalent selective Bruton’s tyrosine kinase (BTK) inhibitor, for chronic lymphocytic leukemia (CLL). Dr Eyre explains that clinical trials have indicated high efficacy of pirtobrutinib for patients with CLL who were previously treated with covalent BTK inhibitors. Dr Eyre further comments on frontline studies comparing pirtobrutinib with immunochemotherapy agents and randomized studies investigating venetoclax-rituximab with or without pirtobrutinib. With pirtobrutinib currently going through the FDA approval process, these trials will provide further evidence in terms of efficacy, tolerability, and safety of the agent. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.